TB Diagnostic Market By Type (Culture based diagnosis, Sputum test, Rapid Molecular Diagnosis, Others), By End-User (Hospitals, Diagnostic labs, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

TB Diagnostic Market By Type (Culture based diagnosis, Sputum test, Rapid Molecular Diagnosis, Others), By End-User (Hospitals, Diagnostic labs, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

The TB Diagnostic Market was valued for $2,066.70 million in 2022 and is estimated to reach $3,102.20 million by 2032, exhibiting a CAGR of 4.1% from 2023 to 2032.

Tuberculosis (TB) is a bacterial infection caused by mycobacterium tuberculosis that primarily affects the lungs. It is a bacterial infection spread through inhaling tiny droplets from the coughs or sneezes of an infected person. TB is mainly diagnosed with the TB skin test (TST) and TB blood tests.

The growth of the TB diagnostic market is driven by an increase in the number of R&D activities, the surge in expenditure on product development by the government & private organizations, increase in the technological advancements of the diagnostics test’s products, and an upsurge in the number of hospital visits of the patients for TB screening. Furthermore, the increase in the prevalence of Tb infection drives the growth of the market. For instance, according to the World Health Organization (WHO), in 2021, an estimated 10.6 million people fell ill with tuberculosis (TB) worldwide.

Moreover, an increase in the research pipeline among diagnostic research organizations and rise in awareness about early tuberculosis screening help in the growth of the market. Furthermore, increase in number of product approval and product launch foster the expansion of the market. For instance, in February 2022, QIAGEN N.V., a leading diagnostic company, announced that its QuantiFERON-TB Gold Plus (QFT-Plus), the fourth generation of the modern gold standard for TB detection, received Chinese NMPA approval as test for active tuberculosis detection.

However, BCG vaccination, inaccurate pap smear testing, and the availability of other types of screening for TB are expected to hinder the growth of the market.

The TB diagnostic market is segmented on the basis of type, end user, and region. On the basis of type, the market is categorized into culture-based diagnosis, sputum smear test, rapid molecular diagnosis, and others. On the basis of end user, the market is classified into hospitals, diagnostic labs, and others. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major companies profiled in the report include Abbott Laboratories, Becton Dickinson and Company, Biomerieux SA, Molbio Diagnostics, Bio-Rad Laboratories, Danaher Corporation, F. Hoffmon La-Roche, Hologic Inc., Qiagen Inc and ThermoFisher Scientific.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the tb diagnostic market analysis from 2022 to 2032 to identify the prevailing tb diagnostic market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the tb diagnostic market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global tb diagnostic market trends, key players, market segments, application areas, and market growth strategies.
New Product Development/ Product Matrix of Key Players
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Criss-cross segment analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)
SWOT Analysis

Key Market Segments

By Type

Culture based diagnosis
Sputum test
Rapid Molecular Diagnosis
Others

By End-User

Hospitals
Diagnostic labs
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

Key Market Players

Abbott Laboratories
Becton Dickinson & Company
Molbio Diagnostics Pvt. Ltd.
Bio-Rad Laboratories, Inc.
Danaher Corporation
Hologic Inc.
Thermo Fisher Scientific Inc.
bioMerieux SA
F. Hoffmann-La Roche Ltd.
Qiagen NV.

Please Note: It will take 7-10 business days to complete the report upon order confirmation.